Monday, December 31, 2018

Shilpa Medicare gets USFDA nod for cancer treatment injection

Shilpa Medicare gets USFDA nod for cancer treatment injection The company has received US Food and Drug Administration (USFDA) approval for its ANDA Irinotecan HCL injection USP in the strengths 40 mg/2mL and 100 mg/5mL (20mg/mL) single dose vials, Shilpa Medicare said in a BSE filing.

from Moneycontrol Business News http://bit.ly/2QeZD2x

No comments:

Post a Comment

Small and midcap stocks may face volatility, but long-term returns still strong: Vikas Khemani

​Every day there was some negative news flow, global concern, geopolitical concern, inflation concern, oil prices, commodity, everything was...